Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
Overview
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Full Title of Study: “A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
Interventions
- Drug: XL844
Participating in This Clinical Trial
Inclusion Criteria
- Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) – Prior treatment with at least 2 systemic chemotherapy regimens for CLL – Life expectancy of >3 months – Adequate liver and kidney function – Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL – Willing to use accepted method of contraception during the course of the study – Negative pregnancy test (females) – Written informed consent Exclusion Criteria:
- Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy) – Investigational drug within 30 days of the start of treatment – Uncontrolled intercurrent illness such as infection or cardiovascular disease – Pregnant or breastfeeding women – Subjects known to be HIV positive
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Exelixis
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.